Cost-effectiveness of intrapleural use of tissue plasminogen activator and DNase in pleural infection: Evidence from the MIST2 randomised controlled trial.
The MIST2 trial showed that combined intrapleural use of tissue plasminogen activator (t-PA) and DNase was effective when compared to single agents or placebo. However, the treatment costs are significant and overall cost-effectiveness of combined therapy remains unclear.An economic evaluation of th...
Hlavní autoři: | Luengo-Fernandez, R, Penz, E, Dobson, M, Psallidas, I, Nunn, A, Maskell, N, Rahman, N |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
European Respiratory Society Publications
2019
|
Podobné jednotky
-
Intrapleural use of tissue plasminogen activator and DNase in pleural infection
Autor: Rahman, N, a další
Vydáno: (2011) -
Intrapleural use of tissue plasminogen activator and DNase in pleural infection.
Autor: Rahman, N, a další
Vydáno: (2011) -
The biological effect of tissue plasminogen (t-PA) activator and DNase intrapleural delivery in pleural infection patients
Autor: Kanellakis, N, a další
Vydáno: (2018) -
PRIMARY RESULT OF THE SECOND MULTICENTRE INTRAPLEURAL SEPSIS (MIST2) TRIAL; RANDOMISED TRIAL OF INTRAPLEURAL TPA AND DNASE IN PLEURAL INFECTION
Autor: Rahman, N, a další
Vydáno: (2009) -
Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients
Autor: Kanellakis, N, a další
Vydáno: (2019)